RSS

trastuzumab

Singapore-based biopharmaceutical company, Prestige Biopharma, and privately-owned pharma company, Alvogen, have entered a license and supply agreement to commercialise trastuzumab biosimilar (Hervelous) in central and eastern Europe. more

News

Biosimilars are increasing in popularity with pharma companies, however, an important consideration for the interested parties is knowing which markets are saturated and which are still open, according to data and analytic company, GlobalData. more

Analysis

The Mundipharma network of independent associated companies has expanded its partnership with biopharma company Celltrion Healthcare to now include exclusive distribution rights to trastuzumab biosimilar, Herzuma, in seven EU markets. more

News

Results from the PANACEA study, recently presented at the San Antonio Breast Cancer Symposium, have suggested that immunotherapy may help to overcome trastuzumab-resistant breast cancer. more

News

The US Food and Drug Administration (FDA) has approved the first biosimilar for the treatment of certain breast and stomach cancers, Ogivri (trastuzumab-dkst). more

News

The US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of the proposed biosimilar trastuzumab for the treatment of breast cancer. more

News

breast-cancer-cells-stained-for-dna-(red)-nfkb-(green)-and-a-reactive-oxygen-species-probe-(blue)-julia-sero-the-icr-2011.jpg

photo: Julia Sero/the ICR

A combination of lapatinib and trastuzumab (Herceptin) before surgery shrinks and may even destroy tumours in women with HER2 positive disease within 11 days, according to new research more

News